| Trial ID: | L6096 |
| Source ID: | NCT03407196
|
| Associated Drug: |
Forxiga
|
| Title: |
Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey
|
| Acronym: |
DAPA-TURK
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Forxiga
|
| Outcome Measures: |
Primary: Change in HbA1c(%), To record the mean change in HbA1C from baseline \[ Time Frame: 6 Months \] Changes over time (6 months) in HbA1c(%) value in these patients., 6 months | Secondary: Changes from baseline in Total body weight [ Time Frame: 6 Months ], The mean changes from mean baselines and at Month 6 in Total body weight., 6 months|Changes from baseline in BMI [ Time Frame: 6 Months ], The mean changes from mean baselines and at Month 6 in BMI, 6 months|Changes from baseline in Systolic Blood Pressures, The mean changes from mean baselines and at Month 6 in Systolic Blood Pressures, 6 months|Changes from baseline in Diastolic Blood Pressures [ Time Frame: 6 Months ], The mean changes from mean baselines and at Month 6 in Diastolic Blood Pressures, 6 months|Discontinuation rates of dapagliflozin in the first 6 months of treatment, Discontinuation rates of dapagliflozin in the first 6 months of treatment, 6 months
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca Turkey | Collaborators: Optimum Contract Research Organization, Turkey
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1683
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2017-05-24
|
| Completion Date: |
2018-02-28
|
| Results First Posted: |
|
| Last Update Posted: |
2018-03-07
|
| Locations: |
Keçiören Training and Research Hospital, Ankara, 06280, Turkey
|
| URL: |
https://clinicaltrials.gov/show/NCT03407196
|
